Pang Phillip

About Pang Phillip

Phillip Pang, M.D., Ph.D., is a physician-scientist and biopharma executive with deep experience in infectious diseases and clinical development. At Vir Biotechnology, he served as Executive Vice President and Chief Medical Officer, and at points also held interim responsibility for research and development. He stepped down from Vir at the end of March 2024 after several years with the company. ([businesswire.com](https://www.businesswire.com/news/home/20240220541768/en/Vir-Biotechnology-Announces-Dr.-Phil-Pang-Will-Step-Down-as-Chief-Medical-Officer?utm_source=openai)) During his tenure at Vir, Dr. Pang played a major role in advancing the company’s clinical portfolio, including programs in COVID-19, hepatitis B, hepatitis delta, and HIV. Vir highlighted his leadership in the development of sotrovimab during the height of the pandemic, as well as his broader contribution to programs aimed at major unmet global medical needs. ([businesswire.com](https://www.businesswire.com/news/home/20240220541768/en/Vir-Biotechnology-Announces-Dr.-Phil-Pang-Will-Step-Down-as-Chief-Medical-Officer?utm_source=openai)) Before joining Vir, he served as Chief Medical Officer at Riboscience LLC, a Roche spinoff focused on small-molecule antivirals. Earlier in his career, he was Program Lead at Gilead Sciences, where he led a large matrix team that contributed to the worldwide approval of the first once-daily, single-pill hepatitis C treatment. His background demonstrates substantial expertise in infectious disease drug development, clinical strategy, and the translation of scientific innovation into approved medicines. ([ondemand.casss.org](https://ondemand.casss.org/b/sp/phil-pang-2451?utm_source=openai))